Diazoles (including Hydrogenated) Patents (Class 514/94)
-
Patent number: 8901106Abstract: Imidazole prodrugs, pharmaceutically acceptable salts, or isomers thereof, of the invention are disclosed, which are useful as modulators of the activity of liver X receptors (LXR). Pharmaceutical compositions containing the compounds and methods of using the compounds are also disclosed.Type: GrantFiled: March 26, 2012Date of Patent: December 2, 2014Assignee: Bristol-Myers Squibb CompanyInventors: Ellen K. Kick, Michael J. Hageman, Victor R. Guarino, Ching-Chiang Su, Chenkou Wei, Jayakumar S. Warrier, Satheesh Nair
-
Publication number: 20140349974Abstract: Treatment of pain and related conditions with oral dosage forms of zoledronic acid is described herein.Type: ApplicationFiled: August 12, 2014Publication date: November 27, 2014Inventor: Herriot Tabuteau
-
Publication number: 20140348916Abstract: Disclosed herein are methods of treating or preventing pain. Typically, a pharmaceutical composition having a therapeutically effective amount of the zoledronic acid is administered to a mammal suffering from pain. The pharmaceutical composition may further comprise an enhancer, which can be a medium chain fatty acid salt, an ester, an ether, or a derivative of a medium chain fatty acid and can have a carbon chain length of from about 4 to about 20 carbon atoms.Type: ApplicationFiled: August 11, 2014Publication date: November 27, 2014Inventor: Herriot Tabuteau
-
Patent number: 8883203Abstract: The invention relates to a pharmaceutical composition and oral dosage forms comprising a bisphosphonate in combination with an enhancer to enhance intestinal delivery of the bisphosphonate to the underlying circulation. Preferably, the enhancer is a medium chain fatty acid or a medium chain fatty acid derivative having a carbon chain length of from 6 to 20 carbon atoms, and the solid oral dosage form is a controlled release dosage form such as a delayed release dosage form.Type: GrantFiled: April 26, 2010Date of Patent: November 11, 2014Assignee: Merrion Research III LimitedInventor: Thomas W. I. Leonard
-
Publication number: 20140329773Abstract: Oral dosage forms of bisphosphonate compounds, such as zoledronic acid, can be used to treat or alleviate pain or related conditions.Type: ApplicationFiled: July 21, 2014Publication date: November 6, 2014Inventor: Herriot Tabuteau
-
Publication number: 20140322231Abstract: Methods for treating neurodegeneration, e.g., sensorineural hearing loss, or a demyelinating disease, using bisphosphonates, ERK kinase inhibitors, and osteoprotegerin (OPG) proteins or nucleic acids.Type: ApplicationFiled: March 18, 2014Publication date: October 30, 2014Applicant: MASSACHUSETTS EYE AND EAR INFIRMARYInventors: Konstantina Stankovic, Michael McKenna, Shyan-Yuan Kao, Albert Edge
-
Publication number: 20140315821Abstract: The invention provides a drug selected from eslicarbazepine acetate and eslicarbazepine, for use in treating or preventing a disorder selected from epilepsy, affective disorders, schizoaffective disorders, bipolar disorders, neuropathic pain and neuropathic pain related disorders, attention disorders, anxiety disorders, sensorimotor disorders, vestibular disorders, and fibromyalgia, in a patient suffering from or susceptible to absence seizures.Type: ApplicationFiled: August 24, 2012Publication date: October 23, 2014Applicant: BIAL - PORTELA & Ca, S.A.Inventor: Patricio Manuel Vieira Araujo Soares Da Silva
-
Publication number: 20140296166Abstract: The present invention provides for methods and compositions for treating, reducing and/or preventing cardiac dysfunction by administering to subject a therapeutically effective amount of a bisphosphonate, prodrug thereof, functional analogue or a pharmaceutically effective salt thereof in an amount sufficient to increase activity of at least one kinase in heart tissue of the subject.Type: ApplicationFiled: November 14, 2012Publication date: October 2, 2014Inventors: Kenneth W. Lyles, Cathleen S. Colon-Emeric, Christopher M. O'Connor, Dennis Abraham, Kent Nilson, Howard Rockman, Graham Russell
-
Publication number: 20140274964Abstract: Provided herein are combination therapies for the treatment of progeroid diseases and conditions, cellular aging, bone diseases, and cardiovascular diseases. The provided combination therapies target the aberrant farnesylation of the mutant lamin A protein progerin, and inhibit farnesyl biosynthesis, lamin A prenylation, and increase progerin clearance.Type: ApplicationFiled: March 13, 2014Publication date: September 18, 2014Inventors: Leslie B. Gordon, Mark W. Kieran, Monica E. Kleinman
-
Publication number: 20140274953Abstract: The described invention provides an ex vivo dynamic multiple myeloma (MM) cancer niche contained in a microfluidic device. The dynamic MM cancer niche includes (a) a three-dimensional tissue construct containing a dynamic ex vivo bone marrow (BM) niche, which contains a mineralized bone-like tissue containing viable osteoblasts self-organized into cohesive multiple cell layers and an extracellular matrix secreted by the viable adherent osteoblasts; and a microenvironment dynamically perfused by nutrients and dissolved gas molecules; and (b) human myeloma cells seeded from a biospecimen composition comprising mononuclear cells and the multiple myeloma cells. The human myeloma cells are in contact with osteoblasts of the BM niche, and the viability of the human myeloma cells is maintained by the MM cancer niche.Type: ApplicationFiled: March 14, 2013Publication date: September 18, 2014Inventors: Woo Lee, Jenny Zilberberg, David Samuel Siegel, Peter Tolias, Hongjun Wang, Wenting Zhang
-
Publication number: 20140256683Abstract: Oral dosage forms of bisphosphonate compounds, such as zoledronic acid, can be used to treat or alleviate pain or related conditions.Type: ApplicationFiled: May 15, 2014Publication date: September 11, 2014Applicant: Antecip Bioventures II LLCInventor: Herriot Tabuteau
-
Publication number: 20140256681Abstract: A combination therapy for treating osteoarthritis is disclosed. The combination therapy includes the co-administration of a steroid and Zoledronic Acid. The coadministration of a steroid decreases the production of cytokines, and, therefore, decreases the pro-inflammatory effects of Zoledronic Acid. The co-administration of Zoledronic Acid with steroids treats osteoarthritis, and helps to prevent the onset of osteoarthritis in patients at risk for osteoarthritis.Type: ApplicationFiled: March 8, 2013Publication date: September 11, 2014Inventor: Ketan Desai
-
Publication number: 20140256682Abstract: A combination therapy for treating osteoarthritis is disclosed. The combination therapy includes the co-administration of a steroid and Zoledronic Acid. The coadministration of a steroid decreases the production of cytokines, and, therefore, decreases the pro-inflammatory effects of Zoledronic Acid. The co-administration of Zoledronic Acid with steroids treats osteoarthritis, and helps to prevent the onset of osteoarthritis in patients at risk for osteoarthritis.Type: ApplicationFiled: March 10, 2014Publication date: September 11, 2014Inventor: Ketan Desai
-
Patent number: 8828974Abstract: The present invention relates to a series of substituted 3-aminopropane phosphinic acid derivatives of formula I: wherein R, R1, P1, P2 and P3 are as defined herein. The compounds of this invention are useful in treating a variety of diseases including but not limited to depression, anxiety, certain psychiatric symptoms, cognitive impairment and schizophrenia.Type: GrantFiled: April 24, 2012Date of Patent: September 9, 2014Assignee: Aventis Pharmaceuticals Inc.Inventors: Yong Mi Choi-Sledeski, Julian Levell, Gregory Bernard Poli, Mark Czekaj, Alan John Collis, Roy Vaz
-
Publication number: 20140249108Abstract: Oral dosage forms of bisphosphonate compounds, such as zoledronic acid, can be used to treat or alleviate pain or related conditions.Type: ApplicationFiled: May 15, 2014Publication date: September 4, 2014Applicant: Antecip Bioventures II LLCInventor: Herriot Tabuteau
-
Publication number: 20140249110Abstract: Oral dosage forms of bisphosphonate compounds, such as zoledronic acid, can be used to treat or alleviate pain or related conditions.Type: ApplicationFiled: May 15, 2014Publication date: September 4, 2014Applicant: Antecip Bioventures II LLCInventor: Herriot Tabuteau
-
Publication number: 20140249109Abstract: Oral dosage forms of bisphosphonate compounds, such as zoledronic acid, can be used to treat or alleviate pain or related conditions.Type: ApplicationFiled: May 15, 2014Publication date: September 4, 2014Applicant: Antecip Bioventures II LLCInventor: Herriot Tabuteau
-
Publication number: 20140249112Abstract: Oral dosage forms of bisphosphonate compounds, such as zoledronic acid, can be used to treat or alleviate pain or related conditions.Type: ApplicationFiled: May 15, 2014Publication date: September 4, 2014Applicant: Antecip Bioventures II LLCInventor: Herriot Tabuteau
-
Publication number: 20140249107Abstract: Oral dosage forms of bisphosphonate compounds, such as zoledronic acid, can be used to treat or alleviate pain or related conditions.Type: ApplicationFiled: May 15, 2014Publication date: September 4, 2014Applicant: Antecip Bioventures II LLCInventor: Herriot Tabuteau
-
Publication number: 20140249113Abstract: Oral dosage forms of bisphosphonate compounds, such as zoledronic acid, can be used to treat or alleviate pain or related conditions.Type: ApplicationFiled: May 15, 2014Publication date: September 4, 2014Applicant: Antecip Bioventures II LLCInventor: Herriot Tabuteau
-
Publication number: 20140249111Abstract: Oral dosage forms of bisphosphonate compounds, such as zoledronic acid, can be used to treat or alleviate pain or related conditions.Type: ApplicationFiled: May 15, 2014Publication date: September 4, 2014Applicant: Antecip Bioventures II LLCInventor: Herriot Tabuteau
-
Publication number: 20140242078Abstract: Methods for treating diseases such as cancer comprising administering a Wnt pathway inhibitor, either alone or in combination with other anti-cancer agents, and monitoring for skeletal-related side effects and/or toxicity.Type: ApplicationFiled: February 3, 2014Publication date: August 28, 2014Applicant: OncoMed Pharmaceuticals, Inc.Inventors: Jakob DUPONT, Robert J. STAGG
-
Publication number: 20140235585Abstract: The present invention relates to substituted diaryl derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals as modulators of sphingosine-1-phosphate receptors.Type: ApplicationFiled: February 19, 2014Publication date: August 21, 2014Applicant: ALLERGAN, INC.Inventors: Janet A. Takeuchi, Ling Li, Wha Bin Im, KEN CHOW
-
Publication number: 20140235588Abstract: The present invention relates to substituted 1H-pyrazol-1,2,4-oxadiazole derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals as modulators of sphingosine-1-phosphate receptors.Type: ApplicationFiled: February 13, 2014Publication date: August 21, 2014Applicant: Allergan, Inc.Inventors: Janet A. Takeuchi, Ling Li, Wha Bin Im, KEN CHOW
-
Publication number: 20140235587Abstract: The present invention relates to substituted pyrazoles, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals as modulators of sphingosine-1-phosphate receptors.Type: ApplicationFiled: February 13, 2014Publication date: August 21, 2014Applicant: Allergan, Inc.Inventors: Janet A. Takeuchi, Ling Li, Wha Bin Im, KEN CHOW
-
Publication number: 20140235589Abstract: The present invention relates to a mixed agrochemical emulsion composition comprising: an organic phosphorous pesticide represented by formula (I) (wherein, R1 represents a C1-4 linear or branched alkyl group; R2 represents a C1-4 linear or branched alkyl group; R3 represents a nitrogenated heterocyclic group which may have a substituent or a group —OR4 (wherein R4 represents a nitrogenated heterocyclic group which may have a substituent; and X and Y each independently represent an oxygen atom or a sulfur atom, wherein Y is a sulfur atom when X is an oxygen atom, and Y is an oxygen atom when X is a sulfur atom); chloropicrin; and a nonionic surfactant. The composition has excellent storage stability and excellent emulsifying properties in water and can be sprayed and applied conveniently by diluting the composition with water, in spite of a fact that both chloropicrin and the organic phosphorous pesticide, which are effective for the control of pests, are contained.Type: ApplicationFiled: October 3, 2012Publication date: August 21, 2014Applicant: ISHIHARA SANGYO KAISHA, LTD.Inventors: Mikio Sekiguchi, Takao Awazu
-
Publication number: 20140234210Abstract: Metal-bisphosphonate nanoparticles are disclosed. Also disclosed are pharmaceutical compositions including the metal-bisphosphonate nanoparticles, methods of preparing the metal-bisphosphonate nanoparticles and materials comprising the nanoparticles, and methods of using the compositions to treat cancer or bone-related disorders (e.g., bone-resorption-related diseases, osteoporosis, Paget's disease, and bone metastases) and as imaging agents.Type: ApplicationFiled: July 9, 2012Publication date: August 21, 2014Applicant: The University of North Carolina at Chapel HillInventors: Wenbin Lin, Demin Liu, Joseph Della Rocca, Stephanie A. Kramer, Christopher Y. Poon
-
Publication number: 20140228324Abstract: The present invention relates to substituted dihydropyrazoles, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals as modulators of sphingosine-1-phosphate receptors.Type: ApplicationFiled: February 13, 2014Publication date: August 14, 2014Applicant: Allergan, Inc.Inventors: Janet A. Takeuchi, Ling Li, Wha Bin Im, Ken Chow
-
Publication number: 20140221317Abstract: The present invention relates to novel amine derivatives, processes for preparing them, pharmaceutical compositions containing them and their use as pharmaceuticals as modulators of sphingosine-1-phosphate receptors.Type: ApplicationFiled: March 18, 2014Publication date: August 7, 2014Applicant: Allergan, Inc.Inventors: PHONG X. NGUYEN, TODD M. HEIDELBAUGH, John R. Cappiello
-
Publication number: 20140205648Abstract: The present invention relates to methods for in situ treatment of malignant cells from a cancer associated with bone. In one method, the treatment is for a primary cancer and entails positioning an implant containing and/or coated with at least one active agent for treating malignant cells directly in/on or indirectly among/near (e.g., by placing the implant in an area immediately proximal to) a site containing the malignant cells. In another method, the treatment includes positioning an implant containing and/or coated with at least one active agent for treating malignant cells directly in/on or indirectly among/near (e.g., by placing the implant in an area immediately proximal to) a surgical site from which malignant cells were previously removed/excised.Type: ApplicationFiled: April 3, 2014Publication date: July 24, 2014Applicant: DePuy Synthes Products, LLCInventor: Maria Maccecchini
-
Patent number: 8772326Abstract: The present invention provides compositions and formulations of compounds having formula (I) and pharmaceutically acceptable derivatives thereof, wherein p, R1, R2 and B are as described generally and in classes and subclasses herein, and additionally provides pharmaceutical compositions thereof, and methods for the use thereof for the treatment of any of a number of injuries, conditions or diseases in which HGF/SF or the activities thereof, or agonists or antagonists thereof have a therapeutically useful role. In addition, methods are provided for treating such diseases or diseases starting at a time after the onset of the injury, condition or disease.Type: GrantFiled: July 9, 2009Date of Patent: July 8, 2014Assignee: Anigion Biomedica Corp.Inventors: Weizhong Cai, Prakash Narayan, Bijoy Panicker, David E. Smith
-
Patent number: 8772268Abstract: Bisphosphonamidate prodrugs of therapeutic bisphosphonate compounds and uses thereof to treat diseases are described.Type: GrantFiled: April 27, 2011Date of Patent: July 8, 2014Assignee: The Johns Hopkins UniversityInventors: Caren Laura Freel Meyers, Marie Webster
-
Publication number: 20140171389Abstract: Administration of TH-302 or another hypoxia activated prodrug in combination with a pharmacological agent that down-regulates or inhibits homology directed repair (HDR) is useful for treating cancer.Type: ApplicationFiled: March 30, 2012Publication date: June 19, 2014Applicant: THRESHOLD PHARMACEUTICALS, INC.Inventor: Karen Curd
-
Publication number: 20140170240Abstract: Phosphoramidate alkylator prodrugs can be used to treat cancer when administered alone or in combination with one or more anti-neoplastic agents.Type: ApplicationFiled: December 10, 2013Publication date: June 19, 2014Applicant: Threshold Pharmaceuticals, Inc.Inventors: Mark Matteucci, Jian-Xin Duan, Hailong Jiao
-
Patent number: 8748410Abstract: The present invention is directed to a method for treating aneurysms in vascular tissue. The method includes administering a bisphosphonate compound to a subject in an amount which is effective against the formation or progression of aneurysm, or which is effective to induce regression of an established aneurysm. In alternative methods, an anti-RANKL neutralizing antibody is administered to the subject to achieve analogous anti-aneurysm effect. The methods of particular advantage in the treatment of subjects having an abdominal aortic aneurysm, a relatively common, and life-threatening, condition.Type: GrantFiled: September 9, 2011Date of Patent: June 10, 2014Assignee: Wisconsin Alumni Research FoundationInventors: Dai Yamanouchi, K. Craig Kent, Bo Liu
-
Publication number: 20140142065Abstract: Provided herein is a method of treating cancer by the administration of binuclear gold(I) compounds in patients in need thereof. The pharmaceutical compounds possess anti-cancer activity such as the induction of cell death, inhibition of cellular proliferation, inhibition of thioredoxin reductase activity, and inhibition of tumor growth in vivo.Type: ApplicationFiled: November 1, 2013Publication date: May 22, 2014Applicant: UNIVERSITY OF HONG KONGInventors: Chi Ming CHE, Taotao ZOU
-
Publication number: 20140135292Abstract: To provide a novel compound that has S1P lyase inhibitory ability and induces a reduction in the number of lymphocytes, or a pharmaceutically acceptable salt thereof, and a pharmaceutical composition containing the compound or pharmaceutically acceptable salt thereof as an active ingredient. A compound represented by the general formula (I): or a pharmaceutically acceptable salt thereof.Type: ApplicationFiled: June 27, 2012Publication date: May 15, 2014Applicant: DAIICHI SANKYO COMPANY, LIMITEDInventors: Nobuo Machinaga, Jun Chiba, Ryuji Hashimoto, Mamoru Otoyo, Ryotaku Inoue
-
Publication number: 20140128349Abstract: Methods and compositions useful for the treatment and/or prevention of muscle weakness in cancer patients. In certain embodiments, the methods of the present invention include administering to a cancer patient a therapeutically or prophylactically effective amount of one or more inhibitors of TGFbeta signaling in combination with one or more benzothiazepine derivatives.Type: ApplicationFiled: March 15, 2013Publication date: May 8, 2014Applicants: Indiana University School of Medicine, The Trustees of Columbia University in the City of New YorkInventors: The Trustees of Columbia University in the City of New York, Indiana University School of Medicine
-
Patent number: 8716266Abstract: The present invention pertains to use of PKC-iota inhibitors for treatment of glioma. In a specific embodiment, the treatment method comprises administering ICA-1 or a salt thereof to a subject with glioma. In another embodiment, the treatment method comprises contacting glioma cells with an effective amount of ICA-1 or a salt thereof.Type: GrantFiled: September 4, 2012Date of Patent: May 6, 2014Assignees: University of South Florida, The United States of America as represented by the Department of Veterans AffairsInventor: Mildred E. Acevedo-Duncan
-
Patent number: 8716229Abstract: Methods for treating neurodegeneration, e.g., sensorineural hearing loss, or a demyelinating disease, using bisphosphonates, ERK kinase inhibitors, and osteoprotegerin (OPG) proteins or nucleic acids.Type: GrantFiled: November 8, 2012Date of Patent: May 6, 2014Assignee: Massachusetts Eye & Ear InfirmaryInventors: Konstantina Stankovic, Michael McKenna, Shyan-Yuan Kao, Albert Edge
-
Publication number: 20140107076Abstract: Preparation, in-vitro and in vivo characterization of novel forms of (1-hydroxy-2-imidazol-1-yl-1-phosphono-ethyl)phosphonic acid, suitable for pharmaceutical compositions in drug delivery systems for humans.Type: ApplicationFiled: March 14, 2013Publication date: April 17, 2014Applicant: THAR PHARMACEUTICALS, INC.Inventor: THAR PHARMACEUTICALS, INC.
-
Publication number: 20140105918Abstract: The present invention relates to a method for the diagnosis or the prognosis of metastasis in prostate cancer which comprises determining if the c-MAF gene is amplified in a primary tumor sample. Likewise, the invention also relates to a method for the diagnosis or the prognosis of metastasis in prostate cancer, as well as to a method for determining the tendency to develop bone metastasis with respect to metastasis in other organs, which comprise determining the c-MAF expression level. Finally, the invention relates to the use of a c-MAF inhibitor as therapeutic target for treating the prostate cancer.Type: ApplicationFiled: October 9, 2013Publication date: April 17, 2014Inventors: ROGER GOMIS, JOËL JEAN-MAIRET
-
Publication number: 20140094436Abstract: Compounds of formula (I), pharmaceutical compositions comprising compounds of formula (I) and methods of inhibiting Hsp90 in a cell, treating or preventing a proliferation disorder in a mammal and treating cancer in a mammal comprising administering a compound of formula (I) to a patient or a cell. Variable R5 is an optionally substituted heteroaryl; an optionally substituted 6 to 14-membered aryl; a bicyclic 9-member heterocycle optionally substituted at any substitutable nitrogen or carbon atoms; or a substituent R18, defined herein. Ring A is an aryl or a heteroaryl optionally further substituted with one or more substituents in addition to R3. Substituent R3 is defined herein.Type: ApplicationFiled: December 11, 2013Publication date: April 3, 2014Applicant: SYNTA PHARMACEUTICALS CORP.Inventors: Weiwen Ying, Zhenjian Du, Kevin Foley
-
Publication number: 20140086901Abstract: Compositions and methods for inhibiting the growth of solid tumors following radiation treatment are described. The compositions and methods target matrix metalloproteinases and bone marrow-derived cells expressing matrix metalloproteinases.Type: ApplicationFiled: November 25, 2013Publication date: March 27, 2014Inventors: John Martin Brown, G-one Ahn, Mitomu Kioi
-
Publication number: 20140072624Abstract: Formulations and unit dose forms of TH-302 and other hypoxia activated prodrugs suitable for oral administration are useful for treating cancer.Type: ApplicationFiled: April 13, 2012Publication date: March 13, 2014Applicant: THRESHOLD PHARMACEUTICALS, INC.Inventors: Donald Jung, Mark Matteucci, Stewart Kroll
-
Publication number: 20140065208Abstract: A method of detecting prostate tumorigenesis in a subject, the method including the steps of (a) obtaining a sample from the prostate of the human subject, (b) detecting quantitatively or semi-quantitatively in the sample a level of expression for PKC-? and (c) comparing the expression level in (b) to a level of expression in a normal control, wherein overexpression of PKC-?, with respect to the control, indicates the presence of prostate cancer in the subject. The present invention is based upon the discovery that PKC-? levels are elevated during prostate tumorigenesis. Furthermore, the proliferation rate of the tumor correlates with the level of PKC-?. The invention also provides methods of treating prostate cancer by administering to the subject a compound that inhibits the expression of PKC-?. The compound can be a small interfering RNA (siRNA) molecule.Type: ApplicationFiled: November 8, 2013Publication date: March 6, 2014Applicants: The United States Government as represented by the Department of Veterans Affairs, UNIVERSITY OF SOUTH FLORIDAInventors: Mildred Enid ACEVEDO-DUNCAN, Hla Y. WIN, Raoul SALUP
-
Patent number: 8664204Abstract: Phosphoramidate alkylator prodrugs can be used to treat cancer when administered alone or in combination with one or more anti-neoplastic agents.Type: GrantFiled: July 12, 2013Date of Patent: March 4, 2014Assignee: Threshold Pharmaceuticals, Inc.Inventors: Mark Matteucci, Jian-Xin Duan, Hailong Jiao
-
Publication number: 20140057875Abstract: Preparation, in-vitro and in vivo characterization of novel forms of (1-hydroxy-2-imidazol-1-yl-1-phosphono-ethyl)phosphonic acid, suitable for pharmaceutical compositions in drug delivery systems for humans.Type: ApplicationFiled: February 13, 2013Publication date: February 27, 2014Applicant: THAR PHARMACEUTICALS, INC.Inventor: THAR PHARMACEUTICALS, INC.
-
Publication number: 20140051669Abstract: Oral dosage forms of bisphosphonate compounds, such as zoledronic acid, can be used to treat or alleviate pain or related conditions.Type: ApplicationFiled: October 25, 2013Publication date: February 20, 2014Applicant: Antecip Bioventures II LLCInventor: Herriot Tabuteau
-
Publication number: 20140045796Abstract: The identification of pO2 lowering agents as transient hypoxia-inducers is disclosed herein. Provided is a method of enhancing the efficacy of a hypoxia-sensitive agent in a subject, by administering to the subject a therapeutically effective amount of the hypoxia-sensitive agent and a therapeutically effective amount of a pO2 lowering agent. Methods of treating a subject with a tumor, by administering to the subject a therapeutically effective amount of a pO2 lowering agent and a therapeutically effective amount of a hypoxia-sensitive agent are also disclosed.Type: ApplicationFiled: April 20, 2012Publication date: February 13, 2014Applicants: H.Lee Moffitt Cancer Center and Research Institute, Inc., Human ServicesInventors: Shingo Matsumoto, Robert J. Gillies, James B. Mitchell, Murali K. Cherukuri, Keita Saito